Page 192 - Drug Class Review
P. 192

Page 126 of 205
             Drug Effectiveness Review Project





                                                                  placebo   N/A   26 weeks   239



















                                                                  rivastigmine 6-12 mg/d   6-12 mg/d   26 weeks   243  50-85 years of age; not able to bear children; met DSM-IV criteria for Alzheimer’s type dementia; met  criteria for probable AD according to NINCDS/ADRDA; MMSE scores of 10-26; had a responsible  Severe and unstable cardiac disease; severe COPD; life threatening conditions  Drugs for coexisting diseases allowed except anticholinergic drugs, health food supplements containing  ACh precursors, putative memory enhancers, insulin, and psychotropic drugs






























                          Drugs   Authors:  Rösler et al. 57    Country: Europe and North America  Novartis Pharma AG, Basle, Switzerland  To assess the effects of RIV on the core domains of AD  Setting: Multi-center (45 centers in North America and Europe)   rivastigmine 1-4 mg/d   1-4 mg/d   26 weeks   243




                          Alzheimer     Year:  1999      Study design: RCT   Sample size: 725   caregiver





















             Final Report Update 1     Efficacy/Effectiveness  STUDY:      FUNDING:   RESEARCH OBJECTIVE:      DESIGN:           INTERVENTION:    Dose:     Duration:     Sample size:   INCLUSION:   EXCLUSION:   OTHER MEDICATIONS/  INTERVENTIONS ALLOWED:     Alzheimer's Drugs
   187   188   189   190   191   192   193   194   195   196   197